On November 2, 2026, TriGemX Bio, Inc. and TCGX Acquisition Corp. filed a Form 425 announcing the confidential submission of a draft registration statement on Form S-4 with the SEC in connection with their proposed business combination.

Key Highlights

  • Draft S-4 submitted confidentially: TCGX Acquisition Corp. (NASDAQ:TCGX) and TriGemX Bio, Inc. have confidentially submitted a draft registration statement on Form S-4 to the SEC, which includes a preliminary proxy statement and preliminary prospectus.
  • Proposed ticker change: According to the filing, the combined company is expected to be listed on Nasdaq under the ticker symbol "TGEM."
  • Closing timeline: The closing of the business combination is expected to occur in the first quarter of 2027, subject to shareholder approval, SEC effectiveness of the registration statement, and Nasdaq listing approval, among other conditions.
  • Lead drug candidate: TriGemX Bio is described in the filing as a biotechnology company focused on elismetrep, characterized as "a potential first-in-class TRPM8 channel blocker for the treatment of migraine."
  • Phase 3 trial update: According to the filing, elismetrep is currently in Phase 3 trials for acute treatment of migraine, with results from the first Phase 3 trial anticipated in mid-2027.
  • TCGX leadership: The filing identifies Chen Yu as Chief Executive Officer and Craig Skaling as Chief Financial Officer of TCGX Acquisition Corp.

TCGX and TriGemX Bio Advance Proposed Combination with Confidential S-4 Submission

TCGX Acquisition Corp., a special purpose acquisition company sponsored by TCGX Sponsor, LLC, an affiliate of TCG Crossover Management, LLC, and TriGemX Bio, Inc. jointly announced on November 2, 2026, the confidential submission of a draft registration statement on Form S-4 to the SEC. The filing states this submission "marks an important milestone toward the completion of the previously announced proposed business combination between TriGemX Bio and TCGX."

The proposed combination, if completed, would result in TriGemX Bio becoming a publicly traded company. According to the filing, TCGX is incorporated as a special purpose acquisition company formed "for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses." The draft S-4 contains a preliminary proxy statement and preliminary prospectus. Once the Registration Statement is declared effective, the filing states that TCGX will mail a definitive proxy statement and final prospectus to its shareholders as of a record date to be established for voting on the combination.

Closing is subject to several conditions identified in the filing, including receipt of requisite TCGX shareholder approval, the Registration Statement being declared effective by the SEC, Nasdaq approval to list the combined company's securities, and other customary closing conditions. The filing notes that "there can be no assurance that the proposed business combination will be completed, or completed on the terms currently contemplated." The filing also contains forward-looking statements, which the companies describe as subject to risks and uncertainties including regulatory approvals, market conditions, and the outcome of shareholder votes, among others noted in the filing's cautionary language.

What Was Disclosed

TCGX Acquisition Corp. and TriGemX Bio, Inc. disclosed via a Form 425 the confidential submission of a draft Form S-4 registration statement to the SEC, marking a step in their proposed business combination, with closing expected in the first quarter of 2027.